Okauchi Shinichiro, Hattori Sou, Ohara Gen, Takayashiki Norio, Satoh Hiroaki
Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan.
Division of Pathology, Mito Medical Center, University of Tsukuba, Mito, Japan.
Cancer Diagn Progn. 2022 Nov 3;2(6):716-719. doi: 10.21873/cdp.10166. eCollection 2022 Nov-Dec.
BACKGROUND/AIM: Long-term survival of patients with small cell lung cancer (SCLC) is rare, and, to the best of our knowledge, there has been no SCLC patient who developed second malignancy after long-term survival.
A 66-year-old woman with a history of smoking was admitted to our hospital with a nodule in her right lung. She was diagnosed with cT2aN3M0 localized-SCLC. Chest irradiation and chemotherapy including etoposide was performed. A new nodule appeared in the right lung more than 7 years after the end of treatment for SCLC. A specimen obtained by bronchoscopic biopsy was pathologically confirmed to be a non-SCLC malignancy.
There is a possibility of tumor development associated with etoposide, which is known to be carcinogenic, or residual tumor development from combined type SCLC. We could not confirm whether it was second malignancy or recurrence after long-term interval. The number of long-term survivors of SCLC is likely to increase in the future. The clinical course of this patient is interesting from the perspective of long-term survival of SCLC patients and might have implications for the treatment of patients with similar clinical course in the future.
背景/目的：小细胞肺癌（SCLC）患者的长期生存极为罕见，据我们所知，尚无SCLC患者在长期生存后发生第二原发性恶性肿瘤。
一名66岁有吸烟史的女性因右肺结节入住我院。她被诊断为cT2aN3M0局限性SCLC。进行了胸部放疗和包括依托泊苷在内的化疗。SCLC治疗结束7年多后，右肺出现了一个新结节。经支气管镜活检获取的标本经病理证实为非SCLC恶性肿瘤。
存在与已知具有致癌性的依托泊苷相关的肿瘤发生可能性，或来自混合型SCLC的残留肿瘤发展。我们无法确定这是第二原发性恶性肿瘤还是长期间隔后的复发。未来SCLC长期生存者的数量可能会增加。从SCLC患者长期生存的角度来看，该患者的临床病程很有趣，可能会对未来类似临床病程患者的治疗产生影响。
